Nemaura Medical Inc. (Form: 8-K, Received: 01/10/2022 06:06:57)

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): January 5, 2022

NEMAURA MEDICAL INC.

(Exact name of registrant as specified in charter)

Nevada

(State or other jurisdiction of incorporation)

001-38355		46-5027260
(Commission File Number)		(IRS Employer Identification No.)

57 West 57th Street Manhattan, NY		10019
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:		+1 (646) 416-8000
N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	NMRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 5, 2022, the Board of Directors of Nemaura Medical, Inc. (the “Company”) appointed Arash Ghadar to serve as the Company’s Chief Operating Officer.

From November 2010 until December 2021, Dr. Ghadar, age 45, served as Technical Director of Datalink Electronics (“Datalink”) in Loughborough, England, where he managed the design team as an autonomous entity within Datalink. He was responsible for management of the day-to-day operations, business planning, legal affairs, finance, sales, and business development of the design team. In this role, he also oversaw numerous technical projects for healthcare and industrial customers that included product development lifecycle, feasibility studies, design, development, prototyping, validation, certification, quality management, and volume manufacturing.

Dr. Ghadar is also currently a non-executive director at Medilink Midlands, the Midlands (England) Life Sciences industry association with a vision to stimulate the growth of the Midlands life science sector. He has a BSc Degree and Masters in Electronics and Control Systems Engineering, where he achieved a First Class degree and Distinction respectively, and he also has a Ph.D. in Biosensors from the University of Warwick (U.K.).

On January 5, 2022, in connection with Dr. Ghadar’s appointment, the Company and Dr. Ghadar entered into a Statement of Main Terms of Employment (the “Statement”). Pursuant to the terms of the Statement, the Company agreed to pay Dr. Ghadar an annual base salary of £105,000 (approximately $142,679) in exchange for his services as Chief Operating Officer. Dr. Ghadar also is eligible to receive a performance related bonus of up to 10%, as well as stock options based on key business and commercial milestones and performance metrics.

The foregoing summary of the Statement does not purport to be complete and is qualified in its entirety by reference to the Statement. A copy of the Statement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On January 10, 2022, the Company issued a press release announcing the hiring of Dr. Ghadar as Chief Operating Officer. The press release is attached hereto as Exhibit 99.1 and, except with regard to the websites referenced therein, is incorporated herein by reference.

Beginning on January 10, 2022, the Company’s management will deliver the investor presentation attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information included in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this Current Report on Form 8-K, including on Exhibits 99.1 and 99.2 hereto, that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, or achievements to differ materially from those expressed or implied. Any forward-looking statement speaks only as of the date made. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

The words "believe," "anticipate," "design," "estimate," "plan," "predict," "seek," "expect," "intend," "may," "could," "should," "potential," "likely," "projects," "continue," "will," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are not guarantees of the future as there are a number of meaningful factors that could cause the Company’s actual results to vary materially from those indicated by such forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors the Company believes are appropriate in the circumstances. Factors which could cause actual results to differ from expectations, many of which are beyond the Company’s control, include, but are not limited to, obtaining regulatory approval for our sugarBEAT device, conducting successful clinical trials, executing agreements required to successfully advance the Company's objectives; retaining the management and scientific team to advance the product; overcoming adverse changes in market conditions and the regulatory environment; obtaining and enforcing intellectual property rights; obtaining adequate financing in the future through product licensing, public or private equity or debt financing or otherwise; dealing with general business conditions and competition; and other factors referenced in the Company’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021, as the same may be updated from time to time. Except as required by law, we do not assume any obligation to update any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description

10.1		Statement of Main Terms of Employment dated January 5, 2022.
99.1		Press release of the registrant.
99.2		Investor presentation of the registrant.
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded with the Inline XBRL document

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEMAURA MEDICAL INC.

	By:	/s/ Dewan F. H. Chowdhury
		Dewan F. H. Chowdhury Chief Executive Officer

Date: January 10, 2022

Exhibit 10.1

STATEMENT OF MAIN TERMS OF EMPLOYMENT

This Statement, together with the Employee Handbook, forms part of your Contract of Employment (except where the contrary is expressly stated) and sets out particulars of the main terms on which Dermal Diagnostics Limited (the Company), Advanced Technology Centre, Loughborough University Science & Enterprise Parks, 5 Oakwood Drive, Loughborough, LE11 3QF

Employs: Arash Ghadar

Your employment will commence on 5^th Jan 2022. No previous employment counts as part of your period of continuous employment.

JOB TITLE

You are employed as Chief Operating Officer and your duties will be as advised by your Line Manager, who will be the company Chief Executive Officer or Deputy CEO. Your duties may be modified from time to time to suit the needs of the business.

PROBATIONARY PERIOD

You join us on an initial probationary period of three months. During this period your work performance and general suitability will be assessed and, if it is satisfactory, your employment will continue. However, if your work performance is not up to the required standard, or you are considered to be generally unsuitable, we may either take remedial action (which may include the extension of your probationary period) or terminate your employment at any time. You will be informed of the outcome of your probationary period by your Line Manager, and you should not consider your probationary period to have passed until such notification has been received. We reserve the right not to apply our full contractual capability and disciplinary procedures during your probationary.

PLACE OF WORK

You will normally be required to work at Advanced Technology Centre, Loughborough University Science & Enterprise Parks, 5 Oakwood Drive, Loughborough, LE11 3QF. You will not be required to work outside the United Kingdom.

HOURS OF WORK

Your normal hours of work are 37.5 per week, worked flexibly, but starting no later than 10.00 am and earliest finish is 4.00 pm, Monday to Friday, breaks are unpaid and in line with the Working Time Regulations. Your normal hours are not variable however, you may be required additional hours when authorised and as necessitated by the needs of the business.

REMUNERATION

Your salary is currently £105,000 per annum payable monthly by BACS as detailed on your pay statement. In your first year of employment your salary will be proportionate to the amount of time left in the year. We will ensure that you always receive no less than the National Minimum Wage/National Living Wage.

A performance related bonus of up to 10% is also offered subject to the delivery of the performance objectives to be agreed.

You will be eligible to receive stock options, the quantum of which will be based on key business and commercial milestones and performance metrics. These will be determined and agreed with you by 30 April 2022, and vest after 3 years subject to the successful delivery of the agreed metrics.

For authorised additional hours worked, you will either be given time off in lieu or paid at your basic rate, at the Manager’s discretion. The date when the time off in lieu is taken is to be mutually agreed and must be taken within the same pay period.

BENEFITS

In addition to any which may be mentioned elsewhere in this statement, your position has the benefit of:

Life Assurance Scheme
Medical Insurance Scheme
Fitness Membership

The details included above do not form part of your contract of employment and may be amended or withdrawn at any time.

COLLECTIVE AGREEMENTS

No collective agreements directly affect your terms and conditions of employment.

ANNUAL LEAVE AND PUBLIC/BANK HOLIDAYS

Your holiday year begins on 1st April and ends on 31st March each year, during which you will receive a paid holiday entitlement of 25 days. Entitlements are pro-rata for part-time employees. In your first holiday year your entitlement will be proportionate to the amount of time left in the holiday year.

Your holiday pay will be based on your average earnings over the previous 52 weeks in which wages were payable. This reference period increased from 12 weeks from 6th April 2020.

Conditions relating to the taking of holidays are shown in the Employee Handbook to which you should refer.

In addition to the annual holiday entitlement, you are allowed the following public/bank holidays each year with pay.

The public/bank holidays each year are:

New Year's Day Spring Bank Holiday

Good Friday Late Summer Bank Holiday (August)

Easter Monday Christmas Day

May Day Boxing Day

Entitlements are pro-rata for part-time employees.

In the event of termination of employment any holidays accrued but not taken will be paid for. However, in the event of you having taken any holidays in the current holiday year, which have not been accrued pro-rata, then the appropriate payments will be deducted from your final pay.

We may require you to take any outstanding annual leave entitlement during your notice period.

OTHER PAID LEAVE

You are entitled to the following types of paid leave subject to any qualifying criteria and notification requirements:

Maternity, paternity, adoption, shared parental leave with pay in line with statutory entitlements in place from time to time.

ii)

Bereavement leave, for immediate family, the length of which is to be determined on an individual basis, paid at full pay.

iii)

In addition, qualifying parents are entitled to parental bereavement leave in line with statutory entitlements in place from time to time;

The details included at [ii] above do not form part of your contract of employment and may be amended or withdrawn at any time.

SICK LEAVE, PAY AND CONDITIONS

Any sickness absence taken is paid in line with the current SSP scheme. Conditions relating to the above are shown in the Employee Handbook to which you should refer.

TRAINING

At the commencement of your employment, you will receive training for your specific job, and as your employment progresses your skills may be extended to encompass new job activities within the business. It is a condition of your employment that you participate in any training deemed necessary by us for you to reach the required levels of attainment standards.

In addition, we encourage employees to undertake external training courses where the period of training may further their career with us. Financial assistance may be provided where your Line Manager believes that the performance of the Company will benefit from your progression. Where it is provided, this will be subject to a training agreement which requires repayment by you to the Company of the cost of the training on a sliding scale in the event of the termination of your employment. Further details are available from your Line Manager.

CAPABILITY AND DISCIPLINARY PROCEDURES

The disciplinary rules and procedures that will apply when dealing with capability or disciplinary issues are shown under the headings “Capability Procedures” and “Disciplinary Procedures” in the Employee Handbook to which you should refer.

CAPABILITY/DISCIPLINARY APPEAL PROCEDURE

Should you be dissatisfied with any decision to take action or dismiss you on capability/disciplinary grounds, you must apply, either verbally or in writing, to a Director within five working days of the decision you are complaining against. The Company will exercise discretion in hearing appeals which are submitted outside of this timeframe. Further information can be found in the Employee Handbook under the heading “Capability/Disciplinary Appeal Procedure” to which you should refer.

GRIEVANCE PROCEDURE

Should you feel aggrieved at any matter relating to your employment, raise a grievance promptly with your Line Manager, either verbally or in writing. Whilst there is no deadline by which grievances must be lodged, it may be more difficult for the Company to effectively deal with your grievance if the complaints relate to something which took place a long time ago. Further information can be found in the Employee Handbook.

NOTICE OF TERMINATION TO BE GIVEN BY EMPLOYER

Up to 3 month’s service – 1 months.

Between 3 month and 12 month – notice increases from 1 month to 3 months after the initial 3 month probationary period is completed; the notice period will then increase from 3 months to 6 months at the rate of 10 days per month for each additional month of employment to a maximum of 6 months.

12 months service or more – 6 months.

NOTICE OF TERMINATION TO BE GIVEN BY EMPLOYEE

Up to 3 month’s service – 1 months.

12 months service or more – 6 months.

PAY IN LIEU OF NOTICE

We reserve the contractual right to give pay in lieu of all or any part of the above notice by either party.

PENSION AND PENSION SCHEME

We operate a contributory pension scheme which you will be auto enrolled into (subject to the conditions of the scheme). Further details are available from Payroll.

SIGNATURE:

/s/ Dewan F. H. Chowdhury

For and on behalf of the Employer

DATE:

January 5, 2022

I acknowledge receipt of this statement and agree that, for the purpose of the Working Time Regulations, any applicable entitlements and provisions constitute a relevant agreement.

SIGNATURE:

/s/ Arash Ghadar

Employee

DATE:

January 5, 2022

Exhibit 99.1

Nemaura Medical Appoints Dr Arash Ghadar as Chief Operating Officer

Loughborough, England – January 10, 2022 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the appointment of Dr Arash (Ash) Ghadar as Chief Operating Officer.

“Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations. He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily within a contract design and manufacturing setting, that will be a true asset for the Company during the commercialization phase of our growth,” commented CEO Dr. Faz Chowdhury.

Prior to joining Nemaura, Dr. Ghadar spent a decade as the Technical Director of Datalink Electronics (Datalink) in Loughborough, England where he managed the design team as an autonomous entity within Datalink. He was responsible for management of the day-to-day operations, business planning, legal affairs, finance, sales, and business development of the design team. In this role, he also oversaw numerous technical projects for healthcare and industrial customers that included product development lifecycle, feasibility studies, design, development, prototyping, validation, certification, quality management, and volume manufacturing.

“I am delighted to join Nemaura, a company with a world-class ambition to transform peoples’ lives. I very much look forward to working with the management and the wider team to successfully commercialize the transformational line of non-invasive products the Company is developing, beginning with our continuous glucose monitoring devices and sensors for patients with diabetes.” said Dr. Ghadar.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

Exhibit 99.2

H.C. WAINWRIGHT BIOCONNECT CONFERENCE JANUARY 10 - 13, 2022, VIRTUAL CONFERENCE Dr Faz Chowdhury, CEO Nasdaq : NMRD

Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive,” and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in Nemaura’s filings with the Securities and Exchange Commission (the “Commission”), including the risks identified under the section captioned “Risk Factors” in Nemaura’s Annual Report on Form 10 - K filed with the Commission on June 29, 2021 as the same may be updated from time to time. Nemaura disclaims any obligation to update information contained in these forward - looking statements whether as a result of new information, future events, or otherwise.

Clinical Need… There are over 463 million people living with diabetes worldwide, and over $ 760 Billion was spent in the U . S . alone in 2019 for diabetes related healthcare expenditure 1 . The total addressable market exceeds $ 150 Billion 2 , 3 , 4 . Obesity and Diabetes are two of the major drivers of the chronic disease epidemic .

Why CGM? BGM Misses the full picture!

Nemaura’s Vision Lead in the Prevention, Management, & Reversal of Type 2 Diabetes using a low - cost, flexible, user - friendly device and digital ecosystem.

Our Approach ▪ Skin mounted (disposable) sensor & (non - disposable) transmitter. Glucose extracted to the surface of the skin ▪ Sensors use well established glucose oxidase enzyme to convert glucose to an electric current signal ▪ Low energy bluetooth sends this to the phone app every 5 minutes where it’s converted to a glucose value and viewed by the user. The information is used in various forms to educate and empower the user to improve health outcomes (and not to make the user become ‘dependent’ on the technology).

Product Positioning sugarBEAT® CGM – Direct sales to consumers that wish to purchase sensors to measure glucose profiles on days they choose. www.sugarBEAT.com BEAT®diabetes Program: a subscription - based diabetes management program. Currently in pilot and plan is to sell to employers and insurers. www.BEATdiabetes.Life MiBoKo ® Consumer Metabolic Health Program – Direct to consumer sales to commence after Beta Phase (Beta was launched in October 2021). Plan is also to sell to employers and insurers globally, driven by the low cost approach. www.Miboko.com

sugarBEAT ® Regulatory Status ▪ CE Approved Class 2b Medical Device in Europe ▪ FDA PMA submitted and review still in progress: • BIMO Audit conducted in December 2021 at Nemaura’s UK facility. A single 483 observation was issued. Company has committed to a full and complete response this quarter. • BIMO Audit of Clinical Investigator site scheduled for this quarter . • Premarket inspection covering FDA's Quality System/Current Good Manufacturing Practice regulations for medical devices (21 CFR Part 820) scheduled for this quarter .

sugarBEAT ® Sales status UK ▪ UK: 200,000 sensors ordered by licensee following soft launch success ▪ Delivered first batch of transmitter devices in December 2021, with rolling bi - weekly/monthly delivery planned. ▪ Purchase order forecast for (approximately) a further 100,000 per month for the next 2 years, totaling over 2 million sensors. ▪ Licensee selling these based on a diabetes management subscription service.

sugarBEAT ® Sales Status - Outside - UK Planning direct to consumer launch of sugarBEAT outside of UK where CE approval is accepted, such as Europe and Middle East.

sugarBEAT ®

sugarBEAT ® Testimonials* MySugarWatch offered me a needle - free blood glucose monitoring solution that’s non - invasive and easy to use. I didn’t even realize I had the My Sugar watch device on my arm as it is so lightweight. It gives me the assurance that my blood sugar reading is accurate, and I have access to my levels on my phone at all times. I was diagnosed with gestational diabetes, and I was informed by my healthcare professional that this may lead to a diagnosis of Type 2 diabetes in the future. Unfortunately, I was diagnosed with Type 2 diabetes after this and I have to manage this diagnosis all by myself and learn to control my blood glucose levels. Using MySugarWatch has alerted me to changes in my blood glucose levels and helped me understand how these changes make an impact on my body and how I am feeling. To have this information at my fingertips gives me so much control to manage my diabetes. I have been a Type 2 diabetic for 10 years. I sporadically manage my blood sugar with a blood glucose monitoring device. I know that if not controlled or managed effectively I can have real highs and lows and not know when this will happen. I was wearing the MySugarWatch device and it alerted me to the fact I was about to have a hypo before it happened. This alert enabled me to quickly balance my medication . * MySugarWatch ® is the UK Licensee brand for sugarBEAT®

sugarBEAT ® Testimonials Volunteer data compared with BGM and Invasive CGM Blue: Finger Prick BGM (Blood glucose meter) Red: Invasive CGM sugarBEAT® Raw data presented (prior to algorithmic conversion, demonstrating tight correlation)

Type 2 Diabetes prevention and management program launched in the U.S.

BEAT ® diabetes – 3 Components ▪ Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence (based on an in - clinic program, subsequently replicated using a virtual program). Sustained long term weight loss achieved without loss of muscle mass ▪ proBEAT Ρ Intermittent glucose profiling – using world’s first daily - wearable glucose sensor, developed in - house ▪ Coaching: digital 24/7 using app, and specialist 1 to 1 coaching

Miboko ‘MIND BODY CONNECT’ A metabolic health program comprising an app and integrated glucose sensor

Miboko : A Mass - Market Consumer Product Download the app and on - board Sensor measures metabolic health score Receive report and weekly targets Applicable to over 80 million people in the U.S. with prediabetes as well as general health - conscious individuals, and obesity market.

Miboko : Key Competition Noom: Over 50 million subscribers, >$400m revenues in 2020 5 Miboko USP: A holistic metabolic health approach to weight loss and better health supported using our proprietary wearable sensor that gives an insight into what’s really happening inside the body

Miboko : Launch Update Marketing activities thus far: restricted mainly to low - key organic social media campaign. Over 5000 registrations during the last few weeks of BETA launch, with more than 60% conversion for on - boarding Large scale marketing campaign planned for 2022

Miboko : Key Competition What about other competition with programs using invasive 10 - 14 day CGM? Invasive CGM’s require a prescription in the U.S. Skin trauma from needle and/or adhesive Reports of pain when pulling sensor filament out of arm These factors may make invasive sensors challenging for a consumer market Needle for inserting sensor

CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and large data set. For monitoring viral infections and lower limb blood circulation tracking the effectiveness of drugs Wearable temperature sensors market is expected to register a CAGR of 8.3% during the forecast period 2021 - 2026 6 Future Product Opportunities Leveraging the BEAT ® Technology A rich portfolio of additional products to complement existing offering and contribute to increased revenues

ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual’s drinking habits . Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Global therapeutic drug monitoring device market to reach $3.37B by 2024 7 Future Product Opportunities Leveraging the BEAT ® Technology

The Team ▪ We are building a world class team ▪ So far includes senior level appointments, with experience from companies including: Dexcom, Lifescan , Abbvie , & Eli Lilly ▪ Hiring for Chief Marketing and Sales Officers – U.S. and EU

The Team – Most recent addition Chief Operating Officer, COO Dr Arash Ghadar : Over 20 years as technical and operational experience, last 10 years as COO of an electronics development and manufacturing c ompany. Dr Ghadar obtained a PhD in Bio - sensors from Warwick University and holds a Bachelors and Masters in Electronics and Control Systems Engineering, respectively, for which he achieved First C lass degrees, and was the highest ranking student on both occasions. Dr Ghadar brings with him manufacturing, operational, and management expertise that strongly complement Nemaura’s growth plans.

Intellectual Property ▪ IP consists of several filed p atents and substantial know - how ▪ Two key sensor - related patents are not yet published, relating to novel device and composition

Summary ▪ CE Class 2b Medical Device Approval – and subsequent user testimonials and order for 200,000 sensors (from UK Licensee) and first batch delivery made in D ecember 2021. ▪ FDA PMA review is in progress; audits in relation to PMA, conducted and in - progress ▪ Simple revenue generation models: Direct to consumer subscription services, direct sales to employers and insurers. ▪ Highly Scalable business model with potential for rapid growth ▪ Cash balance over $26m as of September 30, 2021; last quarterly burn rate approx. $2m/ qtr (plus debt repayment).

References 1. https://www.idf.org/aboutdiabetes/what - is - diabetes/facts - figures.html 2. https://drug - dev.com/global - type - 2 - diabetes - market - set - to - almost - double - to - 58 - 7 - billion/ 3. https ://www.prnewswire.com/news - releases/global - digital - diabetes - market - outlook - to - 2026 - a - 16 - billion - industry - opportunity - 300980794. html 4. https://www.absolutemarketsinsights.com/reports/global - Noninsulin - Therapies - for - Diabetes - Market - 2019 - 2027 - 259 5. https ://www.bloomberg.com/news/articles/2021 - 05 - 25/weight - loss - app - noom - gets - 540 - million - in - silver - lake - led - round 6. https://www.mordorintelligence.com/industry - reports/global - wearable - temperature - sensors - market - industry 7. https://www.grandviewresearch.com/press - release/global - therapeutic - drug - monitoring - market